BCAX (Bicara Therapeutics) Long-Term Debt : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Bicara Therapeutics Long-Term Debt?

Bicara Therapeutics's Long-Term Debt for the quarter that ended in Sep. 2024 was $0.00 Mil.

Bicara Therapeutics Long-Term Debt Historical Data

The historical data trend for Bicara Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bicara Therapeutics Long-Term Debt Chart

Bicara Therapeutics Annual Data

Trend

Dec22

Dec23

Long-Term Debt

Bicara Therapeutics Quarterly Data
	Dec22	Jun23	Sep23	Dec23	Jun24	Sep24
Long-Term Debt	Get a 7-Day Free Trial			-	-	-	-	-

Bicara Therapeutics (NAS:BCAX) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Bicara Therapeutics Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Bicara Therapeutics's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Bicara Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicara Therapeutics Inc (NAS:BCAX) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116

Website

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.